Lacosamide Capsule Formulation for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lacosamide dosage forms, such as immediate-release 'Vimpat®' tablets and modified-release 'Motpoly XR' capsules, result in high fluctuations in drug blood concentrations and adverse reactions, necessitating a need for improved dosage forms that provide sustained efficacy and reduced side effects.
Innovation Solution
A unique combination of immediate-release and extended-release components in a capsule formulation, designed to maintain a steady-state plasma concentration ratio of 1:1.2 to 1:3 and peak-trough fluctuation of 35% to 65%, ensuring stable drug levels and reduced adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high daily dose of lacosamide is administered as immediate release dosage form, then the efficacy in treatment of epilepsy is improved, but the incidence of adverse reactions increases
Solution Approach 1:
The patent divides the total daily dose of lacosamide into multiple release components: an immediate release portion (providing rapid therapeutic effect) and an extended release portion (providing sustained drug levels). This segmentation allows the total therapeutic dose to be achieved while reducing peak plasma concentrations that cause adverse reactions, thereby resolving the contradiction between efficacy and side effects
Solution Approach 2:
The patent changes the release rate parameter of lacosamide by using different dosage forms with distinct release characteristics. The immediate release form provides rapid absorption for quick efficacy, while the extended release form maintains steady plasma levels over time, reducing the Cmax that correlates with adverse reactions. This parameter change in release kinetics resolves the contradiction between achieving high daily dose efficacy and minimizing side effects
2Speed
If immediate release dosage form is used, then rapid therapeutic effect is achieved, but fluctuations in drug blood concentrations increase
Solution Approach 1:
The patent merges two dosage forms with opposite release characteristics into a single combined formulation: the immediate release portion (providing rapid therapeutic effect) and the extended release portion (providing stable, sustained drug levels). This combination allows the benefits of both rapid onset and stable concentration to be achieved simultaneously, resolving the contradiction between speed of effect and concentration stability
Solution Approach 2:
The extended release portion acts as a preliminary sustained foundation that maintains minimum therapeutic levels, while the immediate release portion provides the necessary rapid boost. This preliminary action of the extended release component prevents the sharp fluctuations that would otherwise occur with immediate release alone, resolving the contradiction between rapid effect and concentration stability
3Duration of action of stationary object
If modified release dosage form is used, then duration of treatment is extended, but the ratio between Cmin,ss and Cmax,ss deteriorates
Solution Approach 1:
The patent applies different release qualities to different portions of the total dose: the immediate release portion (with higher release rate) provides the rapid therapeutic effect, while the extended release portion (with lower release rate) maintains steady levels throughout the dosing interval. This local differentiation of release characteristics allows extended duration of action while maintaining an optimal Cmin,ss/Cmax,ss ratio, resolving the contradiction between duration and stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves stable blood concentrations, reduces dose frequency, enhances patient compliance, and minimizes side effects by providing a therapeutically effective amount of lacosamide with favorable pharmacokinetics.
Implementation Method 1
a first portion of lacosamide or a pharmaceutically acceptable salt thereof, which comprises an immediate release (IR) portion of lacosamide or a pharmaceutically acceptable salt thereof and an extended release (ER) portion of lacosamide or a pharmaceutically acceptable salt thereof, wherein the first portion is released at a pH ranging from 1.0 to 8.0
Implementation Method 2
a second dosage form comprising a second portion of lacosamide or a pharmaceutically acceptable salt thereof configured for extended release, wherein the second portion of lacosamide or a pharmaceutically acceptable salt thereof accounts for at least 10% of the total amount of lacosamide or a pharmaceutically acceptable salt thereof in the capsule
Data Source
AI summary
The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.